Sugi Predict

Sugi Predict / Compounds / SCHEMBL527362

SCHEMBL527362

SCHEMBL527362

CC(C)C(=O)CC(=O)c1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLOD2 O00469 1/20 0.55
▸ NPC1 O15118 4/20 0.52
▸ RAB9A P51151 2/20 0.52
▸ PTPN1 P18031 1/20 0.52
▸ HTR7 P34969 1/20 0.50
▸ ALOX12 P18054 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ HPGD P15428 2/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ HTT P42858 2/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.47
▸ CES2 O00748 1/20 0.45
▸ CES1 P23141 1/20 0.45
▸ HSD11B1 P28845 1/20 0.45
▸ DPP4 P27487 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ USP2 O75604 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9481728 0.90 NPC1 (0.47) PLOD2NPC1RAB9APTPN1KMT2A
SCHEMBL4975085 0.84 HTR7 (0.50) PLOD2NPC1RAB9APTPN1HTR7
SCHEMBL10801557 0.83 NPC1 (0.60) NPC1RAB9APTPN1HTR7KMT2A
SCHEMBL6168439 0.82 PLOD2 (0.56) PLOD2NPC1RAB9APTPN1HTR7
SCHEMBL28485298 0.82 NPC1 (0.60) NPC1RAB9AALOX12KMT2ASMN1; SMN2
SCHEMBL2491432 0.81 PLOD2 (0.69) PLOD2NPC1RAB9APTPN1HTR7
SCHEMBL19806689 0.81 ERCC5 (0.56) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL16553571 0.81 GSK3B (0.53) KMT2AHPGDMEN1MAPTALDH1A1
SCHEMBL6419173 0.80 PTPN1 (0.60) NPC1RAB9APTPN1MAPTALDH1A1
SCHEMBL1699093 0.80 KMT2A (0.64) PLOD2NPC1RAB9APTPN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2361906-A1 Process for preparing rosuvastatin AstraZeneca UK Limited (GB) 2011-08-31 — — EP claimed
US-20080207903-A1 Chemical Process ASTRAZENECA UK LIMITED (GB) 2008-08-28 — — US claimed
EP-1871747-A2 PROCESS FOR PREPARING ROSUVASTATIN AstraZeneca UK Limited (GB) 2008-01-02 — — EP claimed
WO-2006067456-A2 PROCESS FOR PREPARING ROSUVASTATIN ASTRAZENECA UK LIMITED (GB) 2006-06-29 — — WO claimed
CN-105254483-B A kind of method for preparing the Dicarbonyl derivatives of 2 methyl 1,3 苏州大学 2017-11-03 — — CN disclosed
EP-2598484-B1 PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF LEK PHARMACEUTICALS (SI) 2016-06-29 — — EP disclosed
EP-2598484-B1 PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF LEK PHARMACEUTICALS (SI) 2016-06-29 — — EP disclosed
CN-105254483-A Method for preparing 2-methyl-1,3-dicarbonyl derivative UNIV SOOCHOW 2016-01-20 — — CN disclosed
EP-2785696-B1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INT (DE) 2015-09-23 — — EP disclosed
US-9085538-B2 Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof LEK PHARMACEUTICALS D.D. (SI) 2015-07-21 — — US disclosed
US-9085538-B2 Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof LEK PHARMACEUTICALS D.D. (SI) 2015-07-21 — — US disclosed
US-9085538-B2 Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof LEK PHARMACEUTICALS D.D. (SI) 2015-07-21 — — US disclosed
WO-2007007119-A1 PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES ASTRAZENECA UK LIMITED (GB) 2007-01-18 — — WO disclosed
WO-2006067456-A2 PROCESS FOR PREPARING ROSUVASTATIN ASTRAZENECA UK LIMITED (GB) 2006-06-29 — — WO disclosed
EP-0252476-B1 Trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)-ethyl]- or ethenyl] tetrahydro-4-hydroxypyran-2-one-derivatives a process for their preparation and the use thereof WARNER LAMBERT CO (US) 1994-02-02 — — EP disclosed
US-5102893-A Anticholestrerol agents WARNER-LAMBERT COMPANY (US) 1992-04-07 — — US disclosed
US-4957971-A Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis WARNER-LAMBERT COMPANY (US) 1990-09-18 — — US disclosed
US-4808621-A Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis WARNER-LAMBERT COMPANY (US) 1989-02-28 — — US disclosed
US-4751229-A Treating fungal infections with substituted-(6-(tetrahydro-4-hydroxy-2-oxo-2H-pyran-2-yl)ethyl)- or ethenyl)pyrazoles WARNER-LAMBERT COMPANY (US) 1988-06-14 — — US disclosed
EP-0252476-A2 Trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)-ethyl]- or ethenyl] tetrahydro-4-hydroxypyran-2-one-derivatives a process for their preparation and the use thereof WARNER-LAMBERT COMPANY (US) 1988-01-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207903-A1 Chemical Process CYP2C9, CYP2B6, CYP7A1 PLOD2 3763/4885NPC1 530/4885RAB9A 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.